Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry
12/04/2024
Hernández-Cruz, B., Otero-Varela, L., Freire-González, M., Busquets-Pérez, N., González, A. J. G., Moreno-Ramos, M., ... & Castrejón, I.
Annals of Rheumatic Diseases
https://doi.org/10.1136/ard-2023-225271
doi: 10.1136/ard-2023-225271